Clinical Presentation and Pharmacological Therapy in Corticobasal Degeneration
Arch Neurol 55:957-961, Kompoliti,K.,et al, 1998
Bent Spine Syndrome
JNNP 60:51-54, Serratrice,G.,et al, 1996
Contrast Agent Overdose Causing Brain Retention of Contrast, Seizures, and Parkinsonism
Neurol 43:836-838, May,E.F.,et al, 1993
Creutzfeldt-Jakob Disease without Periodic Sharp Wave Complexes:A Clinical, EEG, and Path Study
Neurol 38:1056-1060, Zochodne,D.W.,et al, 1988
Amyloid Neuropathy & Tremor in Waldenstrom's Macroglobulinemia
Arch Neurol 37:240-242, Bajada,S.,et al, 1980
Neurologic Manifest. of Infective Endocarditis:A Review
Stroke 4:958, Greenlee,J.E.,et al, 1973
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Thalamic Deep Brain Stimulation for Tremor in Parkinson Disease, Essential Tremor, and Dystonia
Neurol 89:1416-1423, Cury, R.G.,et al, 2017
Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease
JAMA Neurol 73:668-674, Martikainen, M.H.,et al, 2016
Cystic Lesions as a Rare Complication of Deep Brain Stimulation
Mov Disord Clin Pract 3:87-90, Sharma, V.D.,et al, 2016
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Facial Bradykinesia
JNNP 84:681-685, Bologna, M.,et al, 2013
Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism
JAMA Neurol 70:859-866, Savica, R.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Myasthenia Gravis as a Cause of Head Drop in Parkinson Disease
The Neurologist 17:144-146, Uludag, I.F.,et al, 2011
Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Deep Brain Stimulation
Neurologist 13:237-252, Kem,DS. &Kumar,R., 2007
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
The Pull Test:A History
Mov Disord 21:894-899, Hunt,A.L.,et al, 2006
Pallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Arch Neurol 62:554-560,533, Anderson,V.C.,et al, 2005
Ophthalmologic Features of Parkinson's Disease
Neurol 62:177-180, Biousse,V.,et al, 2004
Post-Stroke Movement Disorders; Report of 56 Patients
JNNP 75:1568-1574, Alarcon,F.,et al, 2004
Does This Patient Have Parkinson Disease?
JAMA 289:347-353, Rao,G.,et al, 2003
Therapies for Movement Disorders
Arch Neurol 59:699-702, Goetz,C.G &Hinson,V.K., 2002
Involuntary Movements After Anterior Cerebral Artery Territory Infarction
Stroke 32:258-261, Kim,J.S., 2001
Parkinsonism as the Presenting Manifestation of HIV Infection: Improvement on HAART
Neurol 56:278-279, Hersh,B.P.,et al, 2001
Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease
NEJM 345:956-963, The Deep-Brain Stimulation for Parkinson's Disease, 2001
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Neurologic Side Effects in Neuroleptic-Naive Patients Treated with Haloperidol or Risperidone
Neurol 52:782-785, Rosebush,P.I.&Mazurek,M.F., 1999
Diagnostic Criteria for Parkinson Disease
Arch Neurol 56:33-39, Gelb,D.J.,et al, 1999
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Olanzapine Can Worsen Parkinsonism
Neurol 50:1183-1184, Jimenez-Jimenez,F.J.,et al, 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Low-Dose Clozapine Improves Dyskinesias in Parkinson's Disease
Neurol 48:658-662, Durif,F.,et al, 1997
Mortality from Parkinson Disease
Arch Neurol 54:260-264, Louis,E.D.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Severe but Transient Parkinsonism after Tetanus Vaccination
JNNP 63:258, Reijneveld,J.C.,et al, 1997
Tolcapone in Stable Parkinson's Disease:Efficacy and Safety of Long-Term Treatment
Neurol 49:665-671, Waters,C.H.,et al, 1997
A Survey of Antidepressant Drug Use in Parkinson's Disease
Neurol 49:1168-1170, Richard,I.H.,et al, 1997
Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People
NEJM 334:71-76, Bennett,D.A.,et al, 1996
Delayed Emergence of a Park Dis in 38% of 29 Older Men Initially Dx with Idiop REM Sleep Behavior Disorder
Neurol 46:388-393, Schenck,C.H.,et al, 1996